ClinicalTrials.gg
CompletedNCT04033367Updated Sep 17, 2025Results posted

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

A Phase 4 interventional study of Dupilumab and Placebo in Atopic Dermatitis, sponsored by Sanofi. Completed at 42 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
18th of 50
188 · median 75
Started
2019
the only one that year
Phase 4
24 of 50
4 open now
Registered
26th of 50
by date
Lead sponsor
10 of 50
Sanofi

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 18th largest by enrollment, is the only one that started in 2019, is one of 24 in phase 4, and was the 26th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).

Secondary Objectives:

To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation.

To continue to assess the safety and tolerability throughout the study.

Read the detailed description

Duration per participant was up to 28 weeks.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants, male or female 18 years or older,

  • with diagnosed chronic AD, demonstrated 1) inadequate response to topical medications, 2) expected severity of AD and 3) sleep disturbance.
  • had applied skin emollients (moisturizers) at least 7 days before screening.
  • had applied medium potency topical (TCS) on all active AD lesions at least 7 days before screening.
  • willed and able to comply with all clinic visits and study-related procedures.
  • provided signed .

Exclusion criteria

Exclusion criteria:

Participants excluded from the study:

  • with known to Dupixent, clinical depression, drug abuse history, sleep problems not related to AD, irregular sleep pattern, active/acute infections, severe medical conditions, laboratory abnormalities, any condition that might present unreasonable risk to participants or interfered with study assessment, or any severe concomitant illness(es) that would adversely affect the participant's participation in the study, and of topical .
  • at Baseline, presence of any conditions listed as criteria for study drug discontinuation.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Dupilumab/Dupilumab

    Participants received dupilumab 600 milligrams (mg) (loading dose) injection subcutaneously (SC) on Day 1 followed by dupilumab 300 mg injection SC every 2 weeks (q2w) up to Week 10 in the double-blind (DB) period of 12 weeks. After completion of DB period, participants entered in the open-label extension (OLE) period (Week 12 to 24) and continued to receive dupilumab 300 mg injection SC q2w from Week 12 up to Week 22.

    Drug: Dupilumab

  • Placebo comparator
    Placebo/Dupilumab

    Participants received placebo matching to dupilumab injection SC on Day 1 then followed by placebo injection SC q2w up to Week 10 in the DB period of 12 weeks. After completion of DB period, participants entered in the OLE period (Week 12 to 24) and received dupilumab 600 mg (loading dose) at Week 12 followed by dupilumab 300 mg injection SC q2w up to Week 22.

    Drug: Dupilumab · Drug: Placebo

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

    Also known as: SAR231893

  • DrugPlacebo

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. DB Period: Percent Change From Baseline in Sleep Quality Numerical Rating Scale (NRS) at Week 12

    Sleep quality NRS was used to assess the quality of the participant's previous night's sleep. It was collected on a 11-point scale ranged from 0 (worst possible sleep) to 10 (best possible sleep), where higher score indicated better outcome. Percent change from Baseline in sleep quality NRS at Week 12 was reported in this outcome measure.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. DB Period: Percent Change From Baseline in Peak Pruritus NRS at Week 12

    Peak Pruritus NRS was an assessment tool that was used by participants to report the intensity of their pruritus (itch) during a 24-hour recall period. Participants were asked the following question: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Participants answered the question at the specified time point (for the last 24 hours) on the scale of 0 (no itch) to 10 (worst itch imaginable), where higher scores indicated greater severity.

    Time frame: Baseline, Week 12

  2. DB Period: Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Total Score at Week 12

    SCORAD is a validated scoring index for AD, which consists of 3 components i.e., A =extent or affected body surface area (BSA) assessed as a percentage of each defined body area and reported as the sum of all areas, with a maximum score of 100%. B=severity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using the following scale: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points) and C=subjective symptoms scored by participants on VAS, where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), and subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C to give the SCORAD total score range of 0 to 103, where 0 = no disease to 103 = severe disease. Higher values of SCORAD represent worse outcome.

    Time frame: Baseline, Week 12

  3. DB Period: Change From Baseline in SCORAD Sleep Loss Visual Analog Scale (VAS) Score at Week 12

    SCORAD is a validated scoring index for AD, which combines extent (A, 0-100), severity (B, 0-18), and subjective symptoms (C, 0-20) based on itch and sleeplessness, each scored (0-10). The SCORAD for an individual was calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (i.e., itch and sleeplessness/sleep loss) were each scored by the participant using a VAS ranging from 0 to 10, where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleeplessness). Change from Baseline in SCORAD sleeplessness/sleep loss VAS score is reported in this outcome measure.

    Time frame: Baseline, Week 12

  4. DB Period: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Related Impairment Short Form 8a (SF8a) Total T-Score at Week 12

    PROMIS is a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), Level 2, sleep disturbance measure. In this study, 8- item PROMIS Sleep Related Impairment SF8a that assesses the domain of sleep related impairment in the past 7 days in individuals aged 18 and older, was used. Each item asks the participant to rate the severity of the participant's sleep related impairment during the past 7 days (at each specified visit) on a 5-point scale (1 = not at all; 2 = a little bit; 3 = somewhat; 4 = quite a bit; and 5 = very much) with raw score ranging from 8 to 40; higher scores indicating greater severity of sleep impairment. PROMIS T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. Possible range for T-score is 30 to 80, with higher scores indicating greater severity of sleep impairment.

    Time frame: Baseline, Week 12

  5. DB Period: Change From Baseline in Weekly Average Total Sleep Time (TST) at Week 12

    A sleep diary was designed to gather information about participant's daily sleep pattern. It measured night-time sleep assessments. TST (in minutes) was calculated using the formula: Time of waking up for the day minus time of falling sleep minus Wake After Sleep Onset (WASO), where WASO = time awake after initial sleep onset but before the final awakening for the day. Data for WASO was collected from Question 3 of the Sleep Diary: "Considering all the times you woke up last night, how much time were you awake in total?". Baseline and Post-baseline weekly average data were calculated based on the mean of the data over the 7 days prior to and including the day at the Baseline or at the end of the corresponding week. In this outcome measure, change from Baseline in TST at Week 12 is reported.

    Time frame: Baseline, Week 12

  6. DB Period: Change From Baseline in Weekly Average Sleep Efficiency (SE) at Week 12

    A sleep diary was designed to gather information about participant's daily sleep pattern. It measured night-time sleep assessments. SE was calculated using the formula: (TST divided by \[Time of waking up for the day - Time of trying to fall sleep\]) multiplied by 100 percent (%). TST (in minutes) was calculated using the formula: Time of waking up for the day minus time of falling sleep minus Wake After Sleep Onset (WASO), where WASO = time awake after initial sleep onset but before the final awakening for the day. Baseline and Post-baseline weekly average data were calculated based on the mean of the data over the 7 days prior to and including the day at the Baseline or at the end of the corresponding week. In this outcome measure, change from Baseline in SE at Week 12 is reported.

    Time frame: Baseline, Week 12

  7. DB Period: Change From Baseline in Weekly Average Wake After Sleep Onset (WASO) at Week 12

    A sleep diary was designed to gather information about participant's daily sleep pattern. It measured night-time sleep assessments. WASO = time awake (in minutes) after initial sleep onset but before the final awakening for the day. Data for WASO was collected from Question 3 of the Sleep Diary: "Considering all the times you woke up last night, how much time were you awake in total?". Baseline and Post-baseline weekly average data were calculated based on the mean of the data over the 7 days prior to and including the day at the Baseline or at the end of the corresponding week. In this outcome measure, change from Baseline in WASO at Week 12 is reported.

    Time frame: Baseline, Week 12

  8. DB Period: Change From Baseline in Weekly Average Sleep Onset Latency (SOL) at Week 12

    A sleep diary was designed to gather information about participant's daily sleep pattern. It measured night-time sleep assessments. SOL (in minutes) was calculated using the formula: Time of falling sleep - Time of trying to fall sleep. Baseline and Post-baseline weekly average data were calculated based on the mean of the data over the 7 days prior to and including the day at the Baseline or at the end of the corresponding week. In this outcome measure, change from Baseline in SOL at Week 12 is reported.

    Time frame: Baseline, Week 12

  9. DB Period: Percentage of Participants With Eczema Area Severity Index-50 (EASI-50) (Greater Than or Equal to [>=] 50% Improvement From Baseline) at Week 12

    EASI evaluates severity of participants with AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each body region: 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), and 6 (90% to 100%). Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. Percentage of participants with EASI-50 (\>=50% improvement from Baseline in EASI score) at Week 12 is reported in this outcome measure.

    Time frame: Baseline, Week 12

  10. DB Period: Percentage of Participants With Eczema Area Severity Index-75 (EASI-75) (>= 75% Improvement From Baseline) at Week 12

    EASI evaluates severity of participants with AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each body region: 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), and 6 (90% to 100%). Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. Percentage of participants with EASI-75 (\>=75% improvement from Baseline in EASI score) at Week 12 is reported in this outcome measure.

    Time frame: Baseline, Week 12

  11. DB Period: Change From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 12

    The POEM was a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in children and adults with AD. The format is participant response to 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) based on symptom frequency during the past week (i.e., 0 = 'no days', 1 = '1 to 2 days', 2 = '3 to 4 days', 3 = '5 to 6' days, and 4 = 'every day'). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). Higher scores indicated more severe disease and poor quality of life.

    Time frame: Baseline, Week 12

  12. DB Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12

    DLQI was a 10-item questionnaire that measures the impact of skin disease. Each question was evaluated on a 4-point scale ranged from 0 to 3 where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

    Time frame: Baseline, Week 12

  13. DB Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) were defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (from the first investigational medicinal product \[IMP\] administration to the last IMP administration + 14 days) in DB period.

    Time frame: Baseline up to 14 days after last IMP administration (i.e., up to Week 12)

  14. Entire Study Duration: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. SAEs were defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (from the first IMP administration to the last IMP administration + 14 days).

    Time frame: Baseline up to 14 days after last IMP administration (i.e., up to Week 24)

07

Results

Posted Nov 2, 2022

Participant flow

Study was conducted at 46 centers in 10 countries. A total of 267 participants were screened between 22 August 2019 and 13 April 2021, of which 188 participants were enrolled and randomized. A total of 79 participants failed screening mainly due to not meeting eligibility criteria.

DB Period (Up to Week 12)
Participant flow — DB Period (Up to Week 12)
MilestoneDupilumab/DupilumabPlacebo/Dupilumab
Started12761
Completed12260
Not completed51
Withdrew: Adverse event11
Withdrew: Withdrawal by subject40
OLE Period (Week 12 to Week 24)
Participant flow — OLE Period (Week 12 to Week 24)
MilestoneDupilumab/DupilumabPlacebo/Dupilumab
Started12260
Completed11759
Not completed51
Withdrew: Withdrawal by subject41
Withdrew: Other-unspecified10

Outcome measures

PrimaryDB Period: Percent Change From Baseline in Sleep Quality Numerical Rating Scale (NRS) at Week 12

Sleep quality NRS was used to assess the quality of the participant's previous night's sleep. It was collected on a 11-point scale ranged from 0 (worst possible sleep) to 10 (best possible sleep), where higher score indicated better outcome. Percent change from Baseline in sleep quality NRS at Week 12 was reported in this outcome measure.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
DB Period: Percent Change From Baseline in Sleep Quality Numerical Rating Scale (NRS) at Week 12
percent changeDB Period: DupilumabDB Period: Placebo
DB Period: Percent Change From Baseline in Sleep Quality Numerical Rating Scale (NRS) at Week 12-47.71 ± 27.240-32.98 ± 29.536
Statistical analysis
  • DB Period: Dupilumab vs DB Period: Placebo · Mixed Models Analysis · p = <0.001 (Threshold of significance at 0.05.) · Least square mean difference: -15.52 · 95% CI -24.13 to -6.90Dupilumab versus Placebo
SecondaryDB Period: Percent Change From Baseline in Peak Pruritus NRS at Week 12

Peak Pruritus NRS was an assessment tool that was used by participants to report the intensity of their pruritus (itch) during a 24-hour recall period. Participants were asked the following question: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Participants answered the question at the specified time point (for the last 24 hours) on the scale of 0 (no itch) to 10 (worst itch imaginable), where higher scores indicated greater severity.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
DB Period: Percent Change From Baseline in Peak Pruritus NRS at Week 12
percent changeDB Period: DupilumabDB Period: Placebo
DB Period: Percent Change From Baseline in Peak Pruritus NRS at Week 12-52.45 ± 30.614-23.29 ± 30.075
Statistical analysis
  • DB Period: Dupilumab vs DB Period: Placebo · Mixed Models Analysis · p = <0.001 (Threshold of significance at 0.05.) · Least square mean difference: -27.87 · 95% CI -37.96 to -17.78Dupilumab versus Placebo
SecondaryDB Period: Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Total Score at Week 12

SCORAD is a validated scoring index for AD, which consists of 3 components i.e., A =extent or affected body surface area (BSA) assessed as a percentage of each defined body area and reported as the sum of all areas, with a maximum score of 100%. B=severity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using the following scale: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points) and C=subjective symptoms scored by participants on VAS, where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), and subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C to give the SCORAD total score range of 0 to 103, where 0 = no disease to 103 = severe disease. Higher values of SCORAD represent worse outcome.

Time frame:
Baseline, Week 12
Reported as:
Mean · score on a scale
DB Period: Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Total Score at Week 12
score on a scaleDB Period: DupilumabDB Period: Placebo
DB Period: Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Total Score at Week 12-37.78 ± 17.743-20.55 ± 17.944
Statistical analysis
  • DB Period: Dupilumab vs DB Period: Placebo · Mixed Models Analysis · p = <0.001 (Threshold of significance at 0.05.) · Least square mean difference: -15.06 · 95% CI -20.56 to -9.56Dupilumab versus Placebo
SecondaryDB Period: Change From Baseline in SCORAD Sleep Loss Visual Analog Scale (VAS) Score at Week 12

SCORAD is a validated scoring index for AD, which combines extent (A, 0-100), severity (B, 0-18), and subjective symptoms (C, 0-20) based on itch and sleeplessness, each scored (0-10). The SCORAD for an individual was calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (i.e., itch and sleeplessness/sleep loss) were each scored by the participant using a VAS ranging from 0 to 10, where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleeplessness). Change from Baseline in SCORAD sleeplessness/sleep loss VAS score is reported in this outcome measure.

Time frame:
Baseline, Week 12
Reported as:
Mean · score on a scale
DB Period: Change From Baseline in SCORAD Sleep Loss Visual Analog Scale (VAS) Score at Week 12
score on a scaleDB Period: DupilumabDB Period: Placebo
DB Period: Change From Baseline in SCORAD Sleep Loss Visual Analog Scale (VAS) Score at Week 12-4.85 ± 2.953-2.31 ± 3.024
Statistical analysis
  • DB Period: Dupilumab vs DB Period: Placebo · Mixed Models Analysis · p = <0.001 (Threshold of significance at 0.05.) · Least square mean difference: -2.08 · 95% CI -2.97 to -1.18Dupilumab versus Placebo
SecondaryDB Period: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Related Impairment Short Form 8a (SF8a) Total T-Score at Week 12

PROMIS is a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), Level 2, sleep disturbance measure. In this study, 8- item PROMIS Sleep Related Impairment SF8a that assesses the domain of sleep related impairment in the past 7 days in individuals aged 18 and older, was used. Each item asks the participant to rate the severity of the participant's sleep related impairment during the past 7 days (at each specified visit) on a 5-point scale (1 = not at all; 2 = a little bit; 3 = somewhat; 4 = quite a bit; and 5 = very much) with raw score ranging from 8 to 40; higher scores indicating greater severity of sleep impairment. PROMIS T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. Possible range for T-score is 30 to 80, with higher scores indicating greater severity of sleep impairment.

Time frame:
Baseline, Week 12
Reported as:
Mean · T-score
DB Period: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Related Impairment Short Form 8a (SF8a) Total T-Score at Week 12
T-scoreDB Period: DupilumabDB Period: Placebo
DB Period: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Related Impairment Short Form 8a (SF8a) Total T-Score at Week 12-11.42 ± 6.710-7.77 ± 7.240
Statistical analysis
  • DB Period: Dupilumab vs DB Period: Placebo · Mixed Models Analysis · p = <0.001 (Threshold of significance at 0.05.) · Least square mean difference: -3.61 · 95% CI -5.68 to -1.53Dupilumab versus Placebo
SecondaryDB Period: Change From Baseline in Weekly Average Total Sleep Time (TST) at Week 12

A sleep diary was designed to gather information about participant's daily sleep pattern. It measured night-time sleep assessments. TST (in minutes) was calculated using the formula: Time of waking up for the day minus time of falling sleep minus Wake After Sleep Onset (WASO), where WASO = time awake after initial sleep onset but before the final awakening for the day. Data for WASO was collected from Question 3 of the Sleep Diary: "Considering all the times you woke up last night, how much time were you awake in total?". Baseline and Post-baseline weekly average data were calculated based on the mean of the data over the 7 days prior to and including the day at the Baseline or at the end of the corresponding week. In this outcome measure, change from Baseline in TST at Week 12 is reported.

Time frame:
Baseline, Week 12
Reported as:
Mean · minutes
DB Period: Change From Baseline in Weekly Average Total Sleep Time (TST) at Week 12
minutesDB Period: DupilumabDB Period: Placebo
DB Period: Change From Baseline in Weekly Average Total Sleep Time (TST) at Week 129.00 ± 70.987-6.36 ± 55.620
Statistical analysis
  • DB Period: Dupilumab vs DB Period: Placebo · Mixed Models Analysis · p = 0.297 (Threshold of significance at 0.05.) · Least square mean difference: 9.97 · 95% CI -8.86 to 28.79Dupilumab versus Placebo
SecondaryDB Period: Change From Baseline in Weekly Average Sleep Efficiency (SE) at Week 12

A sleep diary was designed to gather information about participant's daily sleep pattern. It measured night-time sleep assessments. SE was calculated using the formula: (TST divided by \[Time of waking up for the day - Time of trying to fall sleep\]) multiplied by 100 percent (%). TST (in minutes) was calculated using the formula: Time of waking up for the day minus time of falling sleep minus Wake After Sleep Onset (WASO), where WASO = time awake after initial sleep onset but before the final awakening for the day. Baseline and Post-baseline weekly average data were calculated based on the mean of the data over the 7 days prior to and including the day at the Baseline or at the end of the corresponding week. In this outcome measure, change from Baseline in SE at Week 12 is reported.

Time frame:
Baseline, Week 12
Reported as:
Mean · percentage of time in bed spent asleep
DB Period: Change From Baseline in Weekly Average Sleep Efficiency (SE) at Week 12
percentage of time in bed spent asleepDB Period: DupilumabDB Period: Placebo
DB Period: Change From Baseline in Weekly Average Sleep Efficiency (SE) at Week 121.81 ± 6.5931.53 ± 6.018
SecondaryDB Period: Change From Baseline in Weekly Average Wake After Sleep Onset (WASO) at Week 12

A sleep diary was designed to gather information about participant's daily sleep pattern. It measured night-time sleep assessments. WASO = time awake (in minutes) after initial sleep onset but before the final awakening for the day. Data for WASO was collected from Question 3 of the Sleep Diary: "Considering all the times you woke up last night, how much time were you awake in total?". Baseline and Post-baseline weekly average data were calculated based on the mean of the data over the 7 days prior to and including the day at the Baseline or at the end of the corresponding week. In this outcome measure, change from Baseline in WASO at Week 12 is reported.

Time frame:
Baseline, Week 12
Reported as:
Mean · minutes
DB Period: Change From Baseline in Weekly Average Wake After Sleep Onset (WASO) at Week 12
minutesDB Period: DupilumabDB Period: Placebo
DB Period: Change From Baseline in Weekly Average Wake After Sleep Onset (WASO) at Week 12-6.79 ± 22.786-9.19 ± 24.661
SecondaryDB Period: Change From Baseline in Weekly Average Sleep Onset Latency (SOL) at Week 12

A sleep diary was designed to gather information about participant's daily sleep pattern. It measured night-time sleep assessments. SOL (in minutes) was calculated using the formula: Time of falling sleep - Time of trying to fall sleep. Baseline and Post-baseline weekly average data were calculated based on the mean of the data over the 7 days prior to and including the day at the Baseline or at the end of the corresponding week. In this outcome measure, change from Baseline in SOL at Week 12 is reported.

Time frame:
Baseline, Week 12
Reported as:
Mean · minutes
DB Period: Change From Baseline in Weekly Average Sleep Onset Latency (SOL) at Week 12
minutesDB Period: DupilumabDB Period: Placebo
DB Period: Change From Baseline in Weekly Average Sleep Onset Latency (SOL) at Week 12-1.44 ± 19.983-3.37 ± 21.477
SecondaryDB Period: Percentage of Participants With Eczema Area Severity Index-50 (EASI-50) (Greater Than or Equal to [>=] 50% Improvement From Baseline) at Week 12

EASI evaluates severity of participants with AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each body region: 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), and 6 (90% to 100%). Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. Percentage of participants with EASI-50 (\>=50% improvement from Baseline in EASI score) at Week 12 is reported in this outcome measure.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants With Eczema Area Severity Index-50 (EASI-50) (Greater Than or Equal to [>=] 50% Improvement From Baseline) at Week 12
percentage of participantsDB Period: DupilumabDB Period: Placebo
DB Period: Percentage of Participants With Eczema Area Severity Index-50 (EASI-50) (Greater Than or Equal to [>=] 50% Improvement From Baseline) at Week 1289.058.3
SecondaryDB Period: Percentage of Participants With Eczema Area Severity Index-75 (EASI-75) (>= 75% Improvement From Baseline) at Week 12

EASI evaluates severity of participants with AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each body region: 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), and 6 (90% to 100%). Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. Percentage of participants with EASI-75 (\>=75% improvement from Baseline in EASI score) at Week 12 is reported in this outcome measure.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants With Eczema Area Severity Index-75 (EASI-75) (>= 75% Improvement From Baseline) at Week 12
percentage of participantsDB Period: DupilumabDB Period: Placebo
DB Period: Percentage of Participants With Eczema Area Severity Index-75 (EASI-75) (>= 75% Improvement From Baseline) at Week 1260.629.2
SecondaryDB Period: Change From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 12

The POEM was a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in children and adults with AD. The format is participant response to 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) based on symptom frequency during the past week (i.e., 0 = 'no days', 1 = '1 to 2 days', 2 = '3 to 4 days', 3 = '5 to 6' days, and 4 = 'every day'). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). Higher scores indicated more severe disease and poor quality of life.

Time frame:
Baseline, Week 12
Reported as:
Mean · score on a scale
DB Period: Change From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 12
score on a scaleDB Period: DupilumabDB Period: Placebo
DB Period: Change From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 12-13.63 ± 7.496-4.44 ± 6.824
SecondaryDB Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12

DLQI was a 10-item questionnaire that measures the impact of skin disease. Each question was evaluated on a 4-point scale ranged from 0 to 3 where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

Time frame:
Baseline, Week 12
Reported as:
Mean · score on a scale
DB Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12
score on a scaleDB Period: DupilumabDB Period: Placebo
DB Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12-11.82 ± 6.503-7.54 ± 6.801
SecondaryDB Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) were defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (from the first investigational medicinal product \[IMP\] administration to the last IMP administration + 14 days) in DB period.

Time frame:
Baseline up to 14 days after last IMP administration (i.e., up to Week 12)
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsDB Period: DupilumabDB Period: Placebo
Any TEAEs7241
Any TESAEs21
SecondaryEntire Study Duration: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. SAEs were defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (from the first IMP administration to the last IMP administration + 14 days).

Time frame:
Baseline up to 14 days after last IMP administration (i.e., up to Week 24)
Reported as:
Count of participants · Participants
Entire Study Duration: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsDupilumab/DupilumabPlacebo/Dupilumab
Any TEAEs8946
Any TESAEs31

Adverse events

Collected over From the first IMP administration up to Week 12 (for DB period arms) and from first IMP administration in OLE period up to Week 24 (for OLE period arms). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Period: Placebo0/61 (0%)1/61 (1.6%)18/61 (29.5%)
DB Period: Dupilumab0/127 (0%)2/127 (1.6%)26/127 (20.5%)
OLE Period: Placebo/Dupilumab0/60 (0%)0/60 (0%)17/60 (28.3%)
OLE Period: Dupilumab/Dupilumab0/122 (0%)1/122 (0.8%)24/122 (19.7%)
Most frequent serious events
Most frequent serious events
EventDB Period: PlaceboDB Period: DupilumabOLE Period: Placebo/DupilumabOLE Period: Dupilumab/Dupilumab
Bladder Transitional Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/610/1270/600/122
FallInjury, poisoning and procedural complications0/610/1270/601/122
Multiple FracturesInjury, poisoning and procedural complications0/610/1270/601/122
Drug HypersensitivityImmune system disorders0/611/1270/600/122
PolyarthritisMusculoskeletal and connective tissue disorders0/611/1270/600/122
Most frequent other events
Most frequent other events
EventDB Period: PlaceboDB Period: DupilumabOLE Period: Placebo/DupilumabOLE Period: Dupilumab/Dupilumab
Dermatitis AtopicSkin and subcutaneous tissue disorders8/614/1271/603/122
Accidental OverdoseInjury, poisoning and procedural complications0/611/1276/6015/122
ConjunctivitisInfections and infestations3/6112/1277/603/122
HeadacheNervous system disorders5/619/1273/602/122
NasopharyngitisInfections and infestations3/612/1274/602/122

Baseline characteristics

Analysis was performed on intent-to-treat (ITT) analysis set which included all randomized participants with a treatment kit number allocated and recorded in the interactive response technology (IRT) database, regardless of whether the treatment kit was used or not and were analyzed according to the treatment group allocated by randomization.

Age, Continuous
Age, Continuous(years)Dupilumab/DupilumabPlacebo/DupilumabTotal
Mean36.2 ± 14.6834.5 ± 15.3635.7 ± 14.89
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab/DupilumabPlacebo/DupilumabTotal
Female663197
Male613091
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dupilumab/DupilumabPlacebo/DupilumabTotal
American Indian or Alaska Native000
Asian131124
Native Hawaiian or Other Pacific Islander000
Black or African American617
White10346149
More than one race202
Unknown or Not Reported336
08

Study locations

42 sites
  • Investigational Site Number :8400012
    North Little Rock, Arkansas 72117, United States
  • Investigational Site Number :8400002
    Redwood City, California 94063, United States
  • Investigational Site Number :8400001
    Rolling Hills Estates, California 90274, United States
  • Investigational Site Number :8400013
    Colorado Springs, Colorado 80907, United States
  • Investigational Site Number :8400005
    Denver, Colorado 80230, United States
  • Investigational Site Number :8400003
    Sarasota, Florida 34239, United States
  • Investigational Site Number :8400007
    Medford, Oregon 97504, United States
  • Investigational Site Number :8400008
    Charleston, South Carolina 29407, United States
  • Investigational Site Number :0360006
    Phillip, Australian Capital Territory 2606, Australia
  • Investigational Site Number :0360001
    Kogarah, New South Wales 2217, Australia
  • Investigational Site Number :0360007
    Woolloongabba, Queensland 4102, Australia
  • Investigational Site Number :0360003
    Carlton, Victoria 3053, Australia
  • Investigational Site Number :2500001
    Brest, 29200, France
  • Investigational Site Number :2500003
    Nantes, 44093, France
  • Investigational Site Number :2500002
    Paris, 75014, France
  • Investigational Site Number :2500006
    Toulouse, 31059, France
  • Investigational Site Number :2760005
    Bad Bentheim, 48455, Germany
  • Investigational Site Number :2760002
    Frankfurt am Main, 60590, Germany
  • Investigational Site Number :2760006
    Friedrichshafen, 88045, Germany
  • Investigational Site Number :2760001
    Göttingen, 37075, Germany
  • Investigational Site Number :2760004
    Münster, 48149, Germany
  • Investigational Site Number :3760005
    Afula, 18101, Israel
  • Investigational Site Number :3760003
    Jerusalem, 91120, Israel
  • Investigational Site Number :3800005
    Rozzano, Milano 20089, Italy
  • Investigational Site Number :3800006
    Perugia, 06129, Italy
  • Investigational Site Number :3800001
    Pisa, 56126, Italy
  • Investigational Site Number :3800004
    Reggio Calabria, 86100, Italy
  • Investigational Site Number :3800002
    Roma, 168, Italy
  • Investigational Site Number :3800003
    Siena, 53100, Italy
  • Investigational Site Number :7240004
    Granada, Andalusia 18016, Spain
  • Investigational Site Number :7240001
    Barcelona / Sabadell, Castille and León 08208, Spain
  • Investigational Site Number :7240003
    Manises, Valencia 46940, Spain
  • Investigational Site Number :7240006
    Córdoba, 14004, Spain
  • Investigational Site Number :7240008
    Madrid, 28007, Spain
  • Investigational Site Number :7240010
    Madrid, 28922, Spain
  • Investigational Site Number :7240005
    Seville, 41013, Spain
  • Investigational Site Number :7240002
    Valencia, 46026, Spain
  • Investigational Site Number :7560001
    Bern, 3010, Switzerland
  • Investigational Site Number :7840002
    Abu Dhabi, 46713, United Arab Emirates
  • Investigational Site Number :7840001
    Dubai, United Arab Emirates
  • Investigational Site Number :8260002
    Dudley, Birmingham DY1 2HQ, United Kingdom
  • Investigational Site Number :8260004
    Edinburgh, Edinburgh, City of EH16 4SA, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Oct 2021, 25 months.

Results were first posted in Nov 2022, 1 year after primary completion.

Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 25 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2019
First posted
Jul 26, 2019
StartActual
Aug 22, 2019
Primary completionActual
Oct 6, 2021
CompletionActual
Oct 6, 2021
Results first posted
Nov 2, 2022
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04033367
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 26, 2019
Start date
Aug 22, 2019
Primary completion
Oct 6, 2021
Completion
Oct 6, 2021
Results posted
Nov 2, 2022
Last update
Sep 17, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion